タフルプロスト
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/07/13 14:41:56」(JST)
[Wiki en表示]
Tafluprost
|
| Systematic (IUPAC) name |
|
isopropyl (5Z)-7-{(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxybut-1-en-1-yl]-3,5-dihydroxycyclopentyl}hept-5-enoate
|
| Clinical data |
| Trade names |
Saflutan, Taflotan, Tapros, Zioptan |
| AHFS/Drugs.com |
International Drug Names |
Pregnancy
category |
- US: C (Risk not ruled out)
|
| Legal status |
|
Routes of
administration |
Topical (eye drops) |
| Identifiers |
| CAS Registry Number |
209860-87-7 |
| ATC code |
S01EE05 |
| PubChem |
CID: 6433101 |
| ChemSpider |
8044182 |
| UNII |
1O6WQ6T7G3 Y |
| ChEBI |
CHEBI:66899 Y |
| ChEMBL |
CHEMBL1963683 |
| Chemical data |
| Formula |
C25H34F2O5 |
| Molecular mass |
452.531266 g/mol |
SMILES
-
CC(C)OC(=O)CCC\C=C/CC(C(O)CC1O)C1\C=C\C(F)(F)COc2ccccc2
|
Tafluprost (trade names Taflotan, marketed by Santen Pharmaceutical and Zioptan, by Merck (U.S.)) is a prostaglandin analogue used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension. It reduces intraocular pressure by increasing the outflow of aqueous fluid from the eyes.[1][2]
Taflotan contains 15 µg/ml Tafluprost. Taflotan sine is a preservative-free, single-dose formulation containing 0.3 ml per dose.[3]
References
- ^ Schubert-Zsilavecz, M, Wurglics, M, Neue Arzneimittel 2008/2009
- ^ Santen Home Page
- ^ Gelbe Liste (in German)
|
Eicosanoids
|
|
| Precursor |
|
|
| Prostanoids |
| Prostaglandins (PG) |
| Precursor |
|
|
| Active |
| D/J |
|
|
| E/F |
|
|
| I |
- I2 (Prostacyclin/Epoprostenol):
|
|
|
|
| Thromboxanes (TX) |
|
|
|
| Leukotrienes (LT) |
| Precursor |
- Arachidonic acid 5-hydroperoxide
|
|
| Initial |
|
|
| SRS-A |
|
|
|
| Eoxins (EX) |
| Precursor |
- Arachidonic acid 15-hydroperoxide
|
|
| Eoxins |
|
|
|
| Nonclassic |
- Lipoxins (LX) (A4, B4)
- Virodhamine
|
|
| By function |
- vasoconstriction
- vasodilation
- platelets: induce
- inhibit
- leukocytes: induce
- inhibit
- labor stimulation:
- PGE2 (Dinoprostone)
- PGF2α (Dinoprost)
|
|
|
Index of inborn errors of metabolism
|
|
| Description |
- Metabolism
- Enzymes and pathways: citric acid cycle
- pentose phosphate
- glycoproteins
- glycosaminoglycans
- phospholipid
- cholesterol and steroid
- sphingolipids
- eicosanoids
- amino acid
- urea cycle
- nucleotide
|
|
| Disorders |
- Citric acid cycle and electron transport chain
- Glycoprotein
- Proteoglycan
- Fatty-acid
- Phospholipid
- Cholesterol and steroid
- Eicosanoid
- Amino acid
- Purine-pyrimidine
- Heme metabolism
- Symptoms and signs
|
|
| Treatment |
|
|
Index of biochemical families
|
|
| Carbohydrates |
- Alcohols
- Glycoproteins
- Glycosides
|
|
| Lipids |
- Eicosanoids
- Fatty acids
- Glycerides
- Phospholipids
- Sphingolipids
- Steroids
|
|
| Nucleic acids |
|
|
| Proteins |
|
|
| Other |
|
|
|
|
Drugs used for glaucoma preparations and miosis (S01E)
|
|
| Sympathomimetics |
- Apraclonidine
- Brimonidine (+timolol)
- Clonidine
- Dipivefrine
- Epinephrine
|
|
| Parasympathomimetics |
| muscarinic |
|
|
| muscarinic/nicotinic |
|
|
| Acetylcholinesterase inhibitors |
- Demecarium
- Ecothiopate
- Stigmine (Fluostigmine
- Neostigmine
- Physostigmine)
- Paraoxon
|
|
|
Carbonic anhydrase inhibitors/
(sulfonamides) |
- Acetazolamide
- Brinzolamide (+timolol)
- Diclofenamide
- Dorzolamide (+timolol)
- Methazolamide
|
|
| Beta blocking agents |
- Befunolol
- Betaxolol
- Carteolol
- Levobunolol
- Metipranolol
- Timolol
- Mepindolol
|
|
| Prostaglandin analogues (F2α) |
- Bimatoprost (+timolol)
- Latanoprost (+timolol)
- Tafluprost
- Travoprost (+timolol)
- Unoprostone
|
|
| Other agents |
|
|
|
Index of the eye
|
|
| Description |
- Anatomy
- Physiology
- Phenomena
- appearance
- visual
- optical illusions
- proteins
- Development
|
|
| Disease |
- Congenital
- Corneal dystrophy
- Neoplasms and cancer
- Other
- Symptoms and signs
|
|
| Treatment |
- Procedures
- Drugs
- infection
- glaucoma and miosis
- mydriatics
- vascular
|
|
|
|
Prostanoids
|
|
Receptor
(ligands) |
|
|
Enzyme
(inhibitors) |
| Cyclooxygenase |
|
|
| PGD2 synthase |
- Retinoids
- Selenium (selenium tetrachloride, sodium selenite, selenium disulfide)
|
|
| PGE synthase |
HQL-79
|
|
| PGF synthase |
Bimatoprost
|
|
| PGI2 synthase |
Tranylcypromine
|
|
| TXA synthase |
- Camonagrel
- Dazmegrel
- Dazoxiben
- Furegrelate
- Isbogrel
- Midazogrel
- Nafagrel
- Nicogrelate
- Ozagrel
- Picotamide
- Pirmagrel
- Ridogrel
- Rolafagrel
- Samixogrel
- Terbogrel
- U63557A
|
|
|
| Others |
- Precursors: Linoleic acid
- γ-Linolenic acid (gamolenic acid)
- Dihomo-γ-linolenic acid
- Diacylglycerol
- Arachidonic acid
- Prostaglandin G2
- Prostaglandin H2
|
|
|
See also: Leukotrienergics
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Comparison of the ocular surface changes following the use of two different prostaglandin F2α analogues containing benzalkonium chloride or polyquad in rabbit eyes.
- Lee HJ1, Jun RM, Cho MS, Choi KR.
- Cutaneous and ocular toxicology.Cutan Ocul Toxicol.2015 Sep;34(3):195-202. doi: 10.3109/15569527.2014.944650. Epub 2014 Sep 29.
- OBJECTIVE: The aim of this study is to compare the effect of prostaglandin analogues preserved with either 0.015% or 0.001% benzalkoium chloride (BAK); or 0.001% polyquad (PQ) on the ocular surface of rabbit eyes.METHODS: Forty white rabbits were randomized to receive four-times daily instillation o
- PMID 25265260
- In vitro Effects of Prostaglandin Analogs on Cultured Astrocytes Obtained from the Lamina Cribrosa.
- Shin JA1, Kim NW, Kang SS, Kim ML, Sung KR.
- Current eye research.Curr Eye Res.2015 Aug 3:1-7. [Epub ahead of print]
- PURPOSE: To evaluate the effects of prostaglandin analogs (PGAs) on cell viability and apoptosis in cultured astrocytes obtained from the lamina cribrosa (LC) of the human optic nerve head (ONH).METHODS: Astrocytes were cultured from LC samples obtained from human donor ONH and treated with three ki
- PMID 26237412
- Safety and Efficacy of Benzalkonium Chloride-optimized Tafluprost in Japanese Glaucoma Patients With Existing Superficial Punctate Keratitis.
- Suzuki K1, Teranishi S, Sagara T, Yoshino H, Nakayama M, Enoki M, Nuno Y, Hirano S, Wakuta M, Takahashi N, Tokuhisa K, Kondo Y, Shiraishi R, Ishida Y, Sonoda KH; Yamaguchi Glaucoma Study Group.
- Journal of glaucoma.J Glaucoma.2015 Aug;24(6):e145-50. doi: 10.1097/IJG.0000000000000020.
- PURPOSE: To evaluate the safety and efficacy of benzalkonium chloride (BAK)-optimized tafluprost (with a BAK concentration reduced from 0.01% to 0.001%) in glaucoma patients with existing superficial punctate keratitis (SPK).PATIENTS AND METHODS: A prospective, multicenter, open-label study was desi
- PMID 24240881
Japanese Journal
- 0.0015%タフルプロスト/0.5%チモロール配合点眼液(DE-111点眼液)の開放隅角緑内障および高眼圧症を対象としたオープンラベルによる長期投与試験
- タフルプロストおよびトラボプロストの12週間点眼による自覚症状,治療満足度の検討 (特集 第67回日本臨床眼科学会講演集(5))
- 臨床報告 タフルプロスト長期点眼(1年間)による原発開放隅角緑内障眼の視野,視神経乳頭血流・形状の変化
Related Links
- Buy Tafluprost (free acid) (CAS 209860-88-8), a very strong FP receptor agonist, from Santa Cruz Biotechnology. Molecular Formula C22H28F2O5 MW 410.5 ... Synonym: (5E)-7-{2-[(1E)-3,3-Difluoro-4-phenoxy-1-buten-1-yl]-3,5 ...
- Tafluprost reference guide for safe and effective use from the American Society of Health-System Pharmacists (AHFS DI). ... Cautions for Tafluprost Contraindications Manufacturer states none known. 1 Warnings/Precautions
Related Pictures
★リンクテーブル★
[★]
- 英
- tafluprost
- 商
- タプロス
- 関
- 眼科用剤